SQSTM1 and Paget's disease of bone

Calcified Tissue International

Volumn 75, Issue 5, 2004, Pages 347-357

  Layfield, R ^a   Hocking, L J ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

p62; Paget's disease of bone; SQSTM1; UBA domain; Ubiquitin

Indexed keywords

PROTEIN; SEQUESTOSOME 1 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; GENE MUTATION; HEREDITY; HUMAN; NONHUMAN; PAGET BONE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; UBIQUITINATION;

DNA MUTATIONAL ANALYSIS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; OSTEITIS DEFORMANS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; UBIQUITIN;

EID: 11944268320     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-004-0041-0     Document Type: Article

References (99)

1. Kanis JA (1992) Pathophysiology and treatment of Paget's disease of bone. Martin Dunitz, London
2. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 17:465-471
3. Huvos AG (1986) Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 57:1442-1449
4. Montagu MFA (1949) Paget's disease (osteitis deformans) and hereditary. Am J Hum Genet 1:94-95
5. Siris ES (1994) Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arth Rheum 23:222-225
6. Sofaer JA, Holloway SM, Emery AE (1983) A family study of Paget's disease of bone. J Epidemiol Community Health 37:226-231
7. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G (1995) Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 10:663-670
8. Hocking L, Slee F, Cundy T, Nicholson G, Van Hul W, Ralston SH (2000) Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone 26:577-580
9. Haslam SI, van Hul W, Morales-Piga A, Balemans W, San Millan JL, Nakatsuka K, Willems P, Haites ME, Ralston SH (1998) Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911-917
10. Barker DJ (1981) The epidemiology of Paget's disease. Metab Bone Dis Rel Res 3:231-233
11. Siris ES (1996) Seeking the elusive aetiology of Paget's disease: a progress report. J Bone Miner Res 11:1599-1601
12. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH (2000) A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15:2315-2329
13. Shafheutle K, Guyer P, Kellingray S, Barker D, Cooper C (1997) The epidemiology of Paget's disease in Great Britain. [abstract]. Bone 20:O017
14. Tiegs RD, Lohse CM, Wollan PC, Melton LJ (2000) Long-term trends in the incidence of Paget's disease of bone. [abstract]. Bone 27:423-427
15. Rogers J, Jeffrey DR, Watt I (2002) Paget's disease in an archeological population. J Bone Miner Res 17:1127-1134
16. Hughes AE, Shearman AM, Weber JL, Barr RJ, Wallace RG, Osterberg PH, Nevin NC, Mollan RA (1994) Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359-361
17. Cody JD, Singer FR, Roodman GD, Otterund B, Lewis TB, Leppert M, Leach RJ (1997) Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 61:1117-1122
18. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM (2000) Mutations in TNFR SF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24:45-48
19. Nakatsuka K, Nishizawa K, Ralston SH (2003) Phenotypic Characterisation of Early Onset Paget's Disease of Bone Caused by a 27 bp Duplication in the TNFRSF11A Gene. J Bone Miner Res 18:1381-1385
20. Whyte MP, Hughes AE (2002) Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17:26-29
21. Good D, Busfield F, Duffy D, Lovelock PK, Resting JB, Cameron DP, Shaw JT (2001) Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree. J Bone Miner Res 16:33-38
22. Nance MA, Nuttall FQ, Econs MJ, Lyles KW, Viles KD, Vance JM, Pericak-Vance MA, Speer MC (2000) Heterogeneity in Paget disease of the bone. Am J Med Genet 92:303-307
23. Sparks AB, Peterson SN, Bell C, Loftus BJ, Hocking L, Cahill DP, Frassica FJ, Streeten EA, Levine MA, Fraser CM, Adams MD, Broder S, Venter JC, Kinzler KW, Vogelstein B, Ralston SH (2001) Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. Calcif Tissue Int 68:151-155
24. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184
25. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Gallon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119-2127
26. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, Westhovens R, Verbruegen L, Anderson D, Hughes A, Van Hul W (2001) Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 28:104-107
27. Hocking LJ, Herbert CA, Nicholls RK, Williams F, Bennett ST, Cundy T, Nicholson GC, Wuyts W, Van Hul W, Ralston SH (2001) Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 69:1055-1061
28. Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528-543
29. Good DA, Busfield F, Fletcher BH, Duffy DL, Resting JB, Andersen J, Shaw JT (2001) Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 70:517-525
30. Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582-1588
31. Hocking LJ, Lucas GJA, Daroszewska A, Mangion J, Olavesen M, Nicholson GC, Ward L, Bennett ST, Wuyts W, Van Hul W, Ralston SH (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 11:2735-2739
32. Good DA, Busfield F, Duffy D, Kestin J, Shaw TE (2002) Single base-pair deletion of gene encoding Sequestosome 1 (SQSTM1/p62) in Paget's disease of bone. [abstract 04:13]. ANZBMS 12th Annual Scientific Meeting. Adelaide, Australia
33. Hocking LJ, Lucas GJA, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh J, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH (2004) UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis and structural consequences. J Bone Miner Res 19: 1122-1127
34. Johnson-Pais TL, Wisdom JH, Weldon KS, Cody JD, Hansen MF, Singer FR, Leach RJ (2003) Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. J Bone Miner Res 18:1748-1753
35. Geetha T, Wooten MW (2002) Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett 512:19-24
36. Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J (1999) Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol 19:2180-2188
37. Sanz L, Diaz-Meco MT, Nakano H, Moscat J (2000) The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19:1576-1586
38. Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA, Moscat J (2001) The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem 276:7709-7712
39. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J (1999) The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18:3044-3053
40. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
41. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545
42. Darnay BG, Ni J, Moore PA, Aggarwal BB (1999) Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAP) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274:7724-7731
43. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, van der Kaufman S, Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015-1024
44. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353-362
45. McLean W, Olsen BR (2001) Mouse models of abnormal skeletal development and homeostasis. Trends Genet 17:S38-43
46. Duran A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, Diaz-Meco MT (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303-309
47. Puls A, Schmidt S, Grawe F, Stabel S (1997) Interaction of protein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc Natl Acad Sci USA 94:6191-6196
48. Wilson MI, Gill DJ, Perisic O, Quinn MT, Williams RL (2003) PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. Mo1 Cell 12:39-50
49. Lamark T, Perander M, Outzen H, Kristiansen K, Overvatn A, Michaelsen E, Bjorkoy G, Johansen T (2003) Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. J Biol Chem 278:34568-34581
50. Noda Y, Kohjima M, Izaki T, Ota K, Yoshinaga S, Inagaki F, Ito T, Sumimoto H (2003) Molecular recognition in dimerization between FBI domains. J Biol Chem 278:43516-43524
51. Shin J (1998) p62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629-633
52. Kuusisto E, Salminen A, Alafuzoff I (2002) Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 28:228-237
53. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H (2002) p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160:255-263
54. Joung I, Strominger JL, Shin J (1996) Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proc Natl Acad Sci USA 93:5991-5995
55. Ponting CP, Blake DJ, Davies KE, Kendrick-Jones J, Winder SJ (1996) ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends Biochem Sci 21:11-13
56. Rechsteiner M, Rogers SW (1996) PEST sequences and regulation by proteolysis. Trends Biochem Sci 21:267-271
57. Aono J, Yanagawa T, Itoh K, Li B, Yoshida H, Kumagai Y, Yamamoto M, Ishii T (2003) Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem Biophys Res Commun 305:271-277
58. Hofmann K, Bucher P (1996) The UBA domain; a sequence motif present in multiple enzyme classes of the ubiquitination pathway. Trends Biochem Sci 21:172-173
59. Hartmann-Petersen R, Seeger M, Gordon C (2003) Transferring substrates to the 26S proteasome. Trends Biochem Sci 28:26-31
60. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479
61. Wilkinson KD (2000) Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 11:141-148
62. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243:1576-1583
63. Johnson ES, Ma PC, Ota IM, Varshavsky A (1995) A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 270:17442-17456
64. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94-102
65. Galan JM, Haguenauer-Tsapis R (1997) Ubiquitin Lys63 is involved in ubiquitination of a yeast plasma membrane protein. EMBO J 16:5847-5854
66. Spence J, Sadis S, Haas AL, Finley D (1995) A ubiquitin mutant with specific defects in DNA repair and multi-ubiquitination. Mol Cell Biol 15:1265-1273
67. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-361
68. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) TAKl is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-351
69. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N (2002) Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22:992-1000
70. Trompouki E, Hatzivassiliou E, Tsichritzis T, Fanner H, Ashworth A, Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793-796
71. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signaling by deubiquitination. Nature 424:801-805
72. Bertolaet BL, Clarke DJ, Wolff M, Watson MH, Henze M, Divita G, Reed SI (2001) UBA domains of DNA damage-inducible proteins interact with ubiquitin. Nat Struct Biol 8:417-422
73. Wilkinson CR, Seeger M, Hartmann-Petersen R, Stone M, Wallace M, Semple C, Gordon C (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol 3:339-343
74. Chen L, Shinde U, Ortolan TG, Madura K (2001) Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep 2:933-938
75. Funakoshi M, Sasaki T, Nishimoto T, Kobayashi H (2002) Budding yeast Dsk2p is a polyubiquitin-binding protein that can interact with the proteasome. Proc Natl Acad Sci USA 99:745-750
76. Hofmann K, Bucher P (1996) The UBA domain: a sequence motif present in multiple enzyme classes of the ubiquitination pathway. Trends Biochem Sci 21:172-173
77. Schultz J, Milpetz F, Bork P, Ponting CP (1998) SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 95:5857-5864
78. Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS (2003) Structure of the UBA domain of p62 (SQSTM1) and implications for mutations which cause Paget's disease of bone. J Biol Chem 278:37409-37412
79. Vadlamudi RK, Joung I, Strominger JL, Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271:20235-20237
80. Chen L, Madura K (2002) Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol Cell Biol 22:4902-4913
81. Raasi S, Pickart CM (2003) Rad23 UBA domains inhibit 26S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 278:8951-8959
82. Hartmann-Petersen R, Hendil KB, Gordon C (2003) Ubiquitin-binding proteins protect ubiquitin conjugates from disassembly. FEBS Lett 535:77-81
83. Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H (2002) Mallory body-a disease-associated type of sequestosome. Hepatology 35:1053-1062
84. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605
85. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J, Matsumoto K (2000) TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5:649-658
86. Harvey L, Gray T, Beneton MNC, Douglas DL, Kanis JA, Russell RGG (1982) Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology. J Clin Path 35:771-779
87. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41-53
88. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
89. Donaldson KM, Li W, Ching KA, Batalov S, Tsai CC, Joazeiro CA (2003) Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci USA 100:8892-8897
90. Withers-Ward ES, Jowett JB, Stewart SA, Xie YM, Garfinkel A, Shibagaki Y, Chow SA, Shah N, Hanaoka F, Sawitz DG, Armstrong RW, Souza LM, Chen IS (1997) Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol 71:9732-9742
91. Miao F, Bouziane M, Dammann R, Masutani C, Hanaoka F, Pfeifer G, O'Connor TR (2000) 3-Methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins. J Biol Chem 275:28433-28438
92. Bedford FK, Kittler JT, Muller E, Thomas P, Uren JM, Merlo D, Wisden W, Triller A, Smart TG, Moss SJ (2001) GABA(A) receptor cell surface number and subunit stability are regulated by the ubiquitin-like protein Plic-1. Nat Neurosci 4:908-916
93. Mah AL, Perry G, Smith MA, Monteiro MJ (2000) Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J Cell Biol 151:847-862
94. Kleijnen MF, Alarcon RM, Howley PM (2003) The ubiquitin-associated domain of hPLIC-2 interacts with the proteasome. Mol Biol Cell 14:3868-3875
95. Bertolaet BL, Clarke DJ, Wolff M, Watson MH, Henze M, Divita G, Reed SI (2001) UBA domains mediate protein-protein interactions between two DNA damage-inducible proteins. J Mol Biol 313:355-363
96. Layfield R, Alban A, Mayer RJ, Lowe J (2001) The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 27:1-15
97. Layfield R, Cavey JR, Lowe J (2003) Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2:343-356
98. Prag G, Misra S, Jones EA, Ghirlando R, Davies BA, Horazdovsky BF, Hurley JH (2003) Mechanism of ubiquitin recognition by the CUE domain of Vps9p. Cell 113:609-620
99. Falchetti A, Di Stefano M, Marini F, Del Monte F, Mavilia C, Strigoli D, De Feo ML, Isaia G, Masi L, Amedei A, Cioppi F, Ghinoi V, Maddali Bongi S, Di Fede G, Sferrazza C, Rini GB, Melchiorre D, Matucci-Cerinic M, Brandi ML (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian series of patients affected by Pager's disease of bone (PDB). J Bone Miner Res 19: 1013-1017